

Nucleotide Sequence of *Escherichia coli pyrG* Encoding CTP Synthetase*

(Received for publication, October 28, 1985)

Manli Weng, Christopher A. Makaroff‡, and Howard Zalkin

From the Department of Biochemistry, Purdue University, West Lafayette, Indiana 47907

The amino acid sequence of *Escherichia coli* CTP synthetase was derived from the nucleotide sequence of *pyrG*. The derived amino acid sequence, confirmed at the N terminus by protein sequencing, predicts a subunit of 544 amino acids having a calculated M_r of 60,300 after removal of the initiator methionine. A glutamine amide transfer domain was identified which extends from approximately amino acid residue 300 to the C terminus of the molecule. The CTP synthetase glutamine amide transfer domain contains three conserved regions similar to those in GMP synthetase, anthranilate synthase, *p*-aminobenzoate synthase, and carbamoyl-P synthetase. The CTP synthetase structure supports a model for gene fusion of a *trpG*-related glutamine amide transfer domain to a primitive NH_3 -dependent CTP synthetase. The major 5' end of *pyrG* mRNA was localized to a position approximately 48 base pairs upstream of the translation initiation codon. Translation of the gene *eno*, encoding enolase, is initiated 89 base pairs downstream of *pyrG*. The *pyrG-eno* junction is characterized by multiple mRNA species which are ascribed to monocistronic *pyrG* and/or *eno* mRNAs and a *pyrG eno* polycistronic mRNA.

CTP synthetase is a glutamine amidotransferase that catalyzes the terminal reaction in the *de novo* pathway for pyrimidine nucleotide synthesis: $\text{UTP} + \text{ATP} + \text{glutamine} \rightarrow \text{CTP} + \text{ADP} + \text{P}_i + \text{glutamate}$. Similar to other glutamine amidotransferases (1), NH_3 can replace glutamine in which case the products are CTP, ADP, and P_i . *Escherichia coli* CTP synthetase is a complex regulatory enzyme that exhibits both positive and negative cooperative effects and is subject to allosteric activation by GTP (2). Activation by GTP results from an increased rate of formation of a covalent glutamyl enzyme catalytic intermediate. Accordingly, the NH_3 -dependent reaction is unaffected by GTP. There is no evidence for regulation of the expression of the gene *pyrG* which encodes CTP synthetase in *E. coli* (3).

The primary structure required for glutamine amide transfer has been obtained for a number of amidotransferases (4-10). Recent sequence analyses of cloned amidotransferase genes have established the existence of two families of glutamine amide transfer domains, each of approximately 190-200 amino acids (8-12). We have employed site-directed mutagen-

esis to investigate the role of amino acid residues that are important for glutamine amide transfer function (13-15). In the absence of crystallographic data, identification of conserved amino acids in a homologous domain from different enzymes provides a basis for identifying potentially functional residues to be replaced by mutagenesis (15). In addition, analysis of the pattern for fusion of the glutamine amide transfer domain to other functional domains has led to a model for the evolution of amidotransferases having the capacity to utilize NH_3 and glutamine (8). For these reasons, sequences of additional glutamine amidotransferases are of interest.

In this paper, we report the nucleotide sequence of *pyrG* and the derived CTP synthetase amino acid sequence. The CTP synthetase glutamine amide transfer domain contains three conserved regions similar to those in anthranilate synthase, *p*-aminobenzoate synthase, GMP synthetase, and carbamoyl-P synthetase. The CTP synthetase glutamine amide transfer domain is located at the C-terminal end of the molecule, encoded by DNA at the 3' end of the gene, consistent with a model (8) for evolution by gene fusion to augment the function of an NH_3 -dependent enzyme. Experiments to map the 5' and 3' ends of the *pyrG* mRNA led to the finding that *eno*, which encodes enolase, is 89 bp¹ downstream of *pyrG*.

EXPERIMENTAL PROCEDURES²

RESULTS

Subcloning *pyrG*—Plasmid pNF1519 contains *pyrG* in a 4.3-kb *Pst*I fragment of *E. coli* DNA cloned in pBR322 (Fig. 1). *pyrG* was subcloned into vector pUC8 as shown in Fig. 1. Plasmid pMW1 was obtained by ligation of a mixture of *Bam*HI fragments from pNF1519 into the *Bam*HI site of pUC8. Selection for *pyrG*⁺ was by functional complementation of *pyrG* in strain JF646. Plasmid pMW5 was constructed by ligating the 2.6-kb *Sal*I-*Pst*I segment of *E. coli* DNA from pMW1 into the *Sal*I and *Pst*I polylinker sites in pUC8. Further subcloning indicated that DNA at the *Bam*HI and *Kpn*I sites in pMW5 was essential for *pyrG* function.

DNA Sequence—The DNA sequence of *pyrG* was initially determined using fragments isolated from plasmid pMW5. *Rsa*I, *Hpa*II, or *Taq*I digests of plasmid pMW5 or of the *Sal*I-

¹ The abbreviations used are: bp, base pair; kb, kilobase pair.

² Portions of this paper (including "Experimental Procedures" and Figs. 1, 2, 4, 5, and 6) are presented in miniprint at the end of this paper. Miniprint is easily read with the aid of a standard magnifying glass. Full size photocopies are available from the Journal of Biological Chemistry, 9650 Rockville Pike, Bethesda, MD 20814. Request Document No. 85M-3563, cite the authors, and include a check or money order for \$4.40 per set of photocopies. Full size photocopies are also included in the microfilm edition of the Journal that is available from Waverly Press.

* This work was supported by United States Public Health Service Grant GM24658. This is Journal Paper No. 10,525 from the Purdue University Agricultural Experiment Station. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡ Recipient of National Institutes of Health Predoctoral Training Grant GM07211.

*Pst*I insert were ligated into M13mp18 or M13mp19 (Fig. 2A). In addition, specific subfragments were isolated from digests that were obtained using restriction enzymes having 6-bp recognition sequences (Fig. 2B). Finally, the exonuclease III procedure (26) was employed to obtain a set of overlapping sequences from *Nru*I-*Bam*HI and *Bam*HI-*Pst*I segments of the cloned DNA (Fig. 2C). The DNA sequence shown in Fig. 3 extends from 11 bp upstream of the *Nru*I site to the downstream *Pst*I site at nucleotide 2442. The entire sequence was determined on both DNA strands from overlapping fragments.

The derived amino acid sequence of CTP synthetase is shown in Fig. 3. The protein chain of 545 amino acid residues has a calculated molecular weight of 60,450. At nucleotides 2074–2076, an ATG initiates an open reading frame that extends 123 codons to the 3' end of the cloned *E. coli* DNA. By screening protein data banks, the downstream sequence was found to be homologous with that of yeast enolase. Thus, *E. coli eno* is 89 bp downstream from *pyrG*.

CTP Synthetase—Enzyme was purified to homogeneity from cells bearing plasmid pMW5. A single stained protein band was obtained by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. By comparison with proteins of known molecular weight, the CTP synthetase subunit had an estimated molecular weight of 60,000 (Fig. 4).

The N-terminal amino acid sequence of CTP synthetase was determined by automated Edman degradation. The data for 24 cycles were indicative of a pure protein. In the first cycle, a complex mixture was obtained, apparently containing methionine, threonine, and a residue similar to alanine. From cycles 2 through 24, the sequence was identical with that shown in Fig. 3 from Thr-3 to Leu-25. We conclude that Met-1 was removed by processing and the N terminus of the mature enzyme is threonine 2 or a modified form of threonine.

pyrG mRNA—The 5' end of *pyrG* mRNA was mapped by the nuclease S1 procedure (29). A 462-nucleotide *Nru*I-*Bam*HI DNA probe was used which extends from nucleotides 12–473 (Figs. 2 and 3). The probe was labeled with [α - 32 P]dCTP by primer extension or the double-stranded fragment was isolated and 5' end-labeled with [γ - 32 P]ATP and polynucleotide kinase. The results of nuclease S1 mapping are shown in Fig. 5. Two protected fragments of coding strand DNA were obtained (Fig. 5A, lane 2). Noncoding strand DNA did not anneal to RNA and was completely digested (Fig. 5A, lane 4). To confirm that the two transcripts extend into the *pyrG* coding sequence, nuclease S1 mapping was repeated using the 5' end-labeled *Nru*I-*Bam*HI probe. Fig. 5B shows that the same two protected fragments were obtained. The size of the major protected fragment is about 175 nucleotides, and the minor one approximately 255 nucleotides. More precise mapping was obtained by using a DNA sequencing ladder as a size standard (Fig. 5C). These results confirm those obtained with restriction fragment size standards. Corresponding sites for transcription initiation are *overlined* in Fig. 3.

The 3' end of *pyrG* mRNA was mapped with a *Kpn*I-*Pst*I DNA probe that extends from nucleotides 1663–2442 (Figs. 2 and 3). The results of nuclease S1 mapping are shown in Fig. 6. The major products obtained from the coding strand were undigested probe and a fragment of approximately 400 nucleotides (Fig. 6, lane 2). Minor fragments of approximately 420, 530, and 650 nucleotides were also obtained. The same pattern of fragments was obtained when the nuclease S1 concentration was increased 3-fold (data not shown). The noncoding strand DNA probe did not anneal to RNA and was completely digested (Fig. 6, lane 4). These results indicate

that there are multiple species of *pyrG* and *eno* mRNA. An mRNA that anneals and fully protects the probe is suggestive of polycistronic *pyrG eno* mRNA.

DISCUSSION

The nucleotide sequence of *E. coli pyrG* was determined in order to extend our analysis of the relationship of glutamine amidotransferase structure to function. Recent sequence analyses indicate that different amidotransferases contain one of two distinct glutamine amide transfer domains (8–12). In all amidotransferases, a glutamine amide transfer domain is combined by various arrangements with a domain that catalyzes an NH_3 -dependent biosynthetic reaction. This combination endows glutamine amidotransferases with the capacity to catalyze a glutamine-dependent as well as an NH_3 -dependent biosynthetic reaction, both *in vitro* and *in vivo* (13, 14). Both types of glutamine amide transfer domain utilize an active site cysteine to form a covalent glutamyl intermediate for catalysis of amide transfer (13, 14). Amidophosphoribosyltransferase (11) and glucosamine-6-P synthase (12) have a highly conserved glutamine amide transfer domain of approximately 190 amino acids that is characterized by an N-terminal active site cysteine. The second type of glutamine amide transfer domain, in GMP synthetase (30), carbamoyl-P synthetase (7, 10), anthranilate synthase (5), and *p*-aminobenzoate synthase (9), shown in Fig. 7, has three conserved segments. The active site cysteine in segment 2 is usually at a position approximately 80 to 90 amino acids from the N terminus of the domain.

The alignment in Fig. 7 localizes the CTP synthetase glutamine amide transfer domain and establishes its similarity to that in carbamoyl-P synthetase, GMP synthetase, anthranilate synthase, and *p*-aminobenzoate synthase. Using current nomenclature, the CTP synthetase glutamine amide transfer domain is *trpG*-related (8). In GMP synthetase, anthranilate synthase component II, and *p*-aminobenzoate synthase subunit II, the homologous *trpG*-related glutamine amide transfer domain (8) is initiated at the N-terminal residue of the protein chain. By noting that the first block of conserved sequence occurs 46–54 residues from the beginning of the domain in the three preceding enzymes, we estimate that the CTP synthetase glutamine amide transfer domain begins approximately at amino acids 292 to 300. Amino acid residues 1 to approximately 300 should contribute the structure needed for catalyzing the NH_3 -dependent reaction. The glutamine amide transfer domain is fused onto the C-terminal end of the enzyme. Likewise, in carbamoyl-P synthetase, the glutamine amide transfer domain is fused onto the C-terminal end of a protein chain, except that the function of the N-terminal 185-amino-acid segment is unknown.

The conservation of amino acids in region 2 is sufficiently high to predict that the conserved cysteine, residue 379 in CTP synthetase, functions to form the covalent glutamyl intermediate as has been shown for Cys-84 in anthranilate synthase component II (14). Likewise, CTP synthetase His-515 in region 3 is implicated in the proton transfer that is required for ionization of Cys-379 (15). Whereas previous experiments have provided evidence for catalytic roles of cysteinyl and histidyl side chains in regions 2 and 3, respectively, there is no evidence bearing on the possible role of region 1 in glutamine amide transfer.

In a previous analysis of the pattern for fusion of the glutamine amide transfer domain to other protein chains, a model was proposed to explain the evolution of glutamine amidotransferases from primitive NH_3 -dependent enzymes (8). According to this model, after duplication, genes encoding

pyrG Nucleotide Sequence

```

      10      20      30      40      50      60      70
GAGCGTCGTT TTCGCGAAGT GGAGCGTATT GTTGCCCGCG GTGGACTCGA AATGACAGGT GTTGACCTCG

      80      90     100     110     120     130     140
AAACAATGGA AGAAGTCTGG CAACAGGTAA AACGGCAGGA AATTGATCTC TAAGGGAATT ACCCGGTCAA

      150     160     170     180     190     200     210
GCGCCATTGG TGTCATTTTT TAAATGACAA GCGCTTGATT TCGGTCAAAA ACATTTACCC CAAAGGGGCT

      220 (2)   230     240     250     260     270     280
ATTTTCTCAC TCCTGATTTC AATAGTGGCG TGGCGAAGAG GAGGGATAAT GAAAGTTTGT GCCACAGGTC

      290     300 (1)   310     320     330     340     350
ATGTTCCGGT ATACTGCTTT CCCGTCTTGG TTATTCCATC GTCTTTTCAA CCTAACTTCT CAGGTTTCAGC

      360
ATG ACA ACG AAC TAT ATT TTT GTG ACC GCG GGC GTC GTA TCC TCT CTG GGT AAA GGC ATT
Met Thr Thr Asn Tyr Ile Phe Val Thr Gly Gly Val Val Ser Ser Leu Gly Lys Gly Ile
      370
      380
GCC GCA GCC TCC CTC GCA GCC ATT CTT GAA GCC CGT GGC CTC AAT GTG ACC ATC ATG AAA
Ala Ala Ala Ser Leu Ala Ala Ile Leu Glu Ala Arg Gly Leu Asn Val Thr Ile Met Lys
      390
      400
CTG GAT CCG TAC ATC AAC GTC GAT CCA GGT ACT ATC AGC CCA ATC CAA CAC GGG GAA GTG
Leu Asp Pro Tyr Ile Asn Val Asp Pro Gly Thr Met Ser Pro Ile Gln His Gly Glu Val
      410
      420
TTC GTT ACT GAA CAC GGC GCT GAA ACC GAC CTG GAC CTG GGG CAC TAC GAG CGT TTC ATT
Phe Val Thr Glu Asp Gly Ala Glu Thr Asp Leu Asp Leu Gly His Tyr Glu Arg Phe Ile
      430
      440
CGT ACC AAA ATG AGC CGC CGC AAC AAC TTC ACC ACG GGT CGT ATC TAC TCT GAC GTT CTG
Arg Thr Lys Met Ser Arg Val Asn Asn Phe Thr Thr Gly Arg Ile Tyr Ser Asp Val Leu
      450
      460
CGT AAA GAA CGC CGC GGT GAC TAC CTC GGC GCA ACC GTG CAG GTT ATT CCG CAC ATC ACT
Arg Lys Glu Arg Arg Gly Asp Tyr Leu Gly Ala Thr Val Gln Val Ile Pro His Ile Thr
      470
      480
AAC GCA ATC AAA GAG CGC GTG CTG GAA GGT GGC GAA GGT CAT GAC GTA GTA CTG GTA GAA
Asn Ala Ile Lys Glu Arg Val Leu Glu Gly Gly Glu Gly His Asp Val Val Leu Val Glu
      490
      500
ATC GGC GGT ACA GTA GGT GAT ATC GAA TCC TTG CCG TTC CTC GAA GCG ATT CCG CAG ATG
Ile Gly Gly Thr Val Gly Asp Ile Glu Ser Leu Pro Phe Leu Glu Ala Ile Arg Gln Met
      510
      520
GCT GTT GAA ATT GGC CGT GAG CAC ACT CTG TTT ATG CAC CTG ACG CTG GTG CCG TAC ATG
Ala Val Glu Ile Gly Arg Glu His Thr Leu Phe Met His Leu Thr Leu Val Pro Tyr Met
      530
      540
GCA GCG TCT GGT GAA GTC AAA ACC AAA CCG ACT CAG CAC TCT GTA AAA GAG CTG CTC TCC
Ala Ala Ser Gly Glu Val Lys Thr Lys Pro Thr Gln His Ser Val Lys Glu Leu Leu Ser
      550
      560
ATC GGT ATC CAG CCT GAC ATC CTG ATT TGT CGT TCA GAT CGC GCT GTT CCG GCG AAC GAA
Ile Gly Ile Gln Pro Asp Ile Leu Ile Cys Arg Ser Asp Arg Ala Val Pro Ala Asn Glu
      570
      580
CGT CCG AAG ATT GCA TTG TTC TGT AAT GTT CCG GAA AAA GCG GTT ATT TCT CTG AAA GAC
Arg Ala Lys Ile Ala Leu Phe Cys Asn Val Pro Glu Lys Ala Val Ile Ser Leu Lys Asp
      590
      600
GTC GAT TCC ATC TAT AAA ATT CCG GGC CTG TTG AAA TCT CAG GGG CTG GAC GAT TAT ATT
Val Asp Ser Ile Tyr Lys Ile Pro Gly Leu Leu Lys Ser Gln Gly Leu Asp Asp Tyr Ile
      610
      620
TGT AAA CGA TTC AGC TTA AAC TGC CCG GAA GCG AAT CTG TCC GAA TGG GAA CAG GTT ATC
Cys Lys Arg Phe Ser Leu Asn Cys Pro Glu Ala Asn Leu Ser Glu Trp Glu Gln Val Ile
      630
      640
TTC GAA GAA GCG AAC CCG GTA AGT GAA GTC ACC ATC GGT ATG GTC GGC AAG TAC ATT GAA
Phe Glu Glu Ala Asn Pro Val Ser Glu Val Thr Ile Gly Met Val Gly Lys Tyr Ile Glu
      650

```

FIG. 3. Nucleotide sequence of *E. coli* *pyrG*, flanking regions, and translated amino acid sequence of CTP synthetase. The translated sequence of an N-terminal segment of enolase is downstream of CTP synthetase. *Underlined* sequences included: *pyrG* ribosome binding site, *eno* ribosome binding site. Regions corresponding to the major and minor mRNA 5' ends are *overlined* and numbered (1) and (2), respectively.

1280 1310
 CTG CCG GAT GCT TAT AAA TCA GTG ATC GAA GCA CTG AAA CAC GGT GGC CTG AAC AAT CGT
 Leu Pro Asp Ala Tyr Lys Ser Val Ile Glu Ala Leu Lys His Gly Gly Leu Lys Asn Arg
 310 320

1340 1370
 GTC AGC GTC AAC ATC AAA CTG ATC GAT TCA CAA GAT GTT GAA ACG CGC GGC CTT GAA ATC
 Val Ser Val Asn Ile Lys Leu Ile Asp Ser Gln Asp Val Glu Thr Arg Gly Leu Glu Ile
 330 340

1400 1430
 CTT AAA GGT CTG GAC GCA ATC CTC GTA CCT GGC GGT TTC GGC TAT CGT GGC GTA GAA GGC
 Leu Lys Gly Leu Asp Ala Ile Leu Val Pro Gly Gly Phe Gly Tyr Arg Gly Val Glu Gly
 350 360

1460 1490
 ATG ATT ACG ACC GCG CGT TTT GCG CGT GAC AAC AAT ATT CCT TAT CTG GGC ATT TGC CTG
 Met Ile Thr Thr Ala Arg Phe Ala Arg Glu Asn Asn Ile Pro Tyr Leu Gly Ile Cys Leu
 370 380

1520 1550
 GGT ATG CAG GTG GCG TTA ATT GAT TAC GCT CGC CAT GTT GGC AAC ATG GAG AAC GCC AAC
 Gly Met Gln Val Ala Leu Ile Asp Tyr Ala Arg His Val Ala Asn Met Glu Asn Ala Asn
 390 400

1580 1610
 TCT ACG GAA TTT GTG CCA GAC TGT AAG TAC CCG GTT GTG GCG CTG ATT ACC GAG TCG CGC
 Ser Thr Glu Phe Val Pro Asp Cys Lys Tyr Pro Val Val Ala Leu Ile Thr Glu Trp Arg
 410 420

1640 1670
 GAT GAA AAC GGC AAC GTT GAA GTT CGT AGC GAG AAG AGC GAT CTC GGC GGT ACC ATG CGT
 Asp Glu Asn Gly Asn Val Glu Val Arg Ser Glu Lys Ser Asp Leu Gly Gly Thr Met Arg
 430 440

1700 1730
 CTC GGC GCA CAG CAG TGC CAG TTC GTT GAC GAT AGC CTG GTT GCG CAG CTG TAC AAT GCC
 Leu Gly Ala Gln Gln Cys Gln Leu Val Asp Ser Leu Val Arg Gln Leu Tyr Asn Ala
 450 460

1760 1790
 CCG ACA ATT GTT GAG CGT CAT CGT CAC CGT TAC GAA GTC AAC AAC AGT CTG TTG AAA CAC
 Pro Thr Ile Val Glu Arg His Arg His Arg Tyr Glu Val Asn Asn Ser Leu Leu Lys Gln
 470 480

1820 1850
 ATT GAA GAT GCA GGT CTG CGC GTT CCG GCG CGT TCC GGG GAT GAT CAG TTG GTC GAG ATC
 Ile Glu Asp Ala Gly Leu Arg Val Arg Ala Arg Ser Gly Asp Asp Gln Leu Val Glu Ile
 490 500

1880 1910
 ATC GAA GTT CCG AAT CAC CCG TGG TTC GTG GCT TGC CAG TTC CAT CCG GAG TTT ACT TCT
 Ile Glu Val Pro Asn His Pro Trp Phe Val Ala Cys Gln Phe His Pro Glu Phe Thr Ser
 510 520

1940 1970
 ACT CCA CGT GAT GGT CAC CCG CTG TTT GCA GGC TTT GTG AAA GCC GCC AGC GAG TTC CAG
 Thr Pro Arg Asp Gly His Pro Leu Phe Ala Gly Phe Val Lys Ala Ala Ser Glu Phe Gln
 530 540

1998 2008 2018 2028 2038
 AAA CGT CAG GCG AAG TAA GTAAAAAAGT TAGAGCGGCA ACGTACCCTG GGTACGGGTT GTTTGTCTGG
 Lys Arg Gln Ala Lys End

2048 2058 2068 2100
 AGTTTCAGTT TAACTAGTGA CTTCAGGAAA ACCTA ATG TCC AAA ATC GTA AAA ATC ATC GGT
 Met Ser Lys Ile Val Lys Ile Ile Gly

2130 2160
 CGT GAA ATC ATC GAC TCC CGT GGT AAC CCG ACT GTT GAA GCC GAA GTA CAT CTG GAG GGT
 Arg Glu Ile Ile Asp Ser Arg Gly Asn Pro Thr Val Glu Ala Glu Val His Leu Glu Gly

2190 2220
 GGT TTC GTC GGT ATG GCA GCT GCT CCG TCA GGT GCT TCT ACT GGT TCC CGT GAA GCT CTG
 Gly Phe Val Gly Met Ala Ala Ala Pro Ser Gly Ala Ser Thr Gly Ser Arg Glu Ala Leu

2250 2280
 GAA CTG CGC GAT GGC GAC AAA TCC CGT TTC CTG GGT AAA GGC GTA ACC AAA GCT GTT GCT
 Glu Leu Arg Asp Gly Asp Lys Ser Arg Phe Leu Gly Lys Gly Val Thr Lys Ala Val Ala

2310 2340
 GCG GTA AAC GGC CCG ATC GCT CAG CCG CTG ATT GGC AAA GAT GCT AAA GAT CAG GCT GGC
 Ala Val Asn Gly Pro Ile Ala Gln Ala Leu Ile Gly Lys Asp Ala Lys Asp Gln Ala Gly

2370 2400
 ATT GAC AAG ATC ATG ATC GAC CTG GAC GGC ACC GAA AAC AAA TCC AAA TTC GGC GCG AAC
 Ile Asp Lys Ile Met Ile Asp Leu Asp Gly Thr Glu Asn Lys Ser Lys Phe Gly Ala Asn

2430
 GCA ATC CTG GCT GTA TCT CTG GCT AAC GCC AAA GCT GCT GCA
 Ala Ile Leu Ala Val Ser Leu Ala Asn Ala Lys Ala Ala Ala

FIG. 3—continued.

	60	90	190
GMPS NH ₂ -53	-- I I L S G G P --	19 -- V P V F G V C Y G M Q T M A M Q L G --	79 -- G V Q F H P E -- 23 -- /
AS II NH ₂ -54	-- L M L S P G P --	19 -- L P I I G I C L G H Q A I V E A Y G --	70 -- G F Q F H P E -- 33 -- /
PABS NH ₂ -46	-- I V I S P G P --	19 -- L P I L G V C L G H Q A M A Q A F G --	73 -- G V Q F H P E -- 17 -- CO ₂ H
CPS NH ₂ -236	- I F L S N G P - -	20 - - I P V F G I C L G H Q L L A L A S G - -	68 - - S F Q G H P E - - 27 - - CO ₂ H
CTPS NH ₂ -345	- A I L V P G G - -	20 - - I P Y L G I C L G M Q V A L I D Y A - -	120 - A C Q F H P E - - 28 - - CO ₂ H

FIG. 7. Alignment of amino acids in three conserved segments of the glutamine amide transfer domain in *E. coli* GMP synthetase (GMPS) (8, 30), anthranilate synthase component II (AS II) (5), *p*-aminobenzoate synthase subunit II (PABS) (9), carbamoyl-P synthetase (CPS) (7), and CTP synthetase (CTPS). The numbers between dashes indicate the number of amino acids from the N terminus (NH₂), between segments, and to the CO₂ terminus (CO₂H) or to the end of the domain (/). The numbering system at the top, as used previously (8), counts all positions, including gaps, from the start of the domain.

a glutamine amide transfer domain translocated adjacent to operons encoding existing NH₃-dependent enzymes. It was suggested that the patterns of fusion were apparently determined by the inability of a glutamine amide transfer domain to translocate contiguous to a promoter. The arrangement of the glutamine amide transfer domain in CTP synthetase conforms to this model. Nuclease S1 mapping indicates that the major *pyrG* promoter is proximal to the translation initiation codon. No other genes intervene between the promoter and *pyrG*. The position of the glutamine amide transfer domain in CTP synthetase is consistent with translocation and fusion of a *trpG*-related glutamine amide transfer domain to the 3' promoter distal end of an existing *pyrG* coding sequence of approximately 300 amino acids.

To explain the *trpG* (5, 31, 32) and *pabA* (9) gene fusion pattern in several microorganisms, it was proposed that *trpG*-related gene fusions onto the 3' end of an existing gene were unfavorable compared to 5' end fusions (8). It is now apparent that 3' end *trpG*-related gene fusions occur in carbamoyl-P synthetase (7, 33) and CTP synthetase. It is uncertain why 3' end *trpG* or *trpG*-related gene fusions did not occur with *trpE* or *pabB*, respectively.

Previously, evidence was reported (34) that *E. coli* CTP synthetase is a dimer (M_r = approximately 105,000) of identical subunits that undergoes aggregation to a tetramer of M_r = approximately 210,000. A subunit M_r = approximately 50,000 was determined by polyacrylamide gel electrophoresis in 8 M urea. The present experiments indicate a calculated M_r = 60,450 for the primary translation product. Removal of the initiator methionine residue should yield a protein chain having a calculated M_r = 60,300. The calculated value of 60,300 is consistent with the results of sodium dodecyl sulfate-polyacrylamide gel electrophoresis. NH₂-terminal protein sequencing verifies that the correct initiator methionine was identified.

Analysis of the *pyrG* 3' flanking sequence indicates an ATG translation start 86 bp downstream from the *pyrG* TAA translation termination triplet. The ATG, position 2074, is preceded by a ribosome binding site (underlined) and starts an open reading frame that extends to the end of the cloned *E. coli* DNA. The translated sequence exhibits 57% identity with yeast enolase (35) and thus identifies *E. coli eno* immediately downstream of *pyrG*. The gene order on the *E. coli* linkage map (36) at min 59, *pyrG relA relX eno*, must therefore be revised to *eno pyrG relA* (16) based on DNA sequence analysis.

Nuclease S1 mapping of the *pyrG eno* boundary indicates multiple species of mRNA. One of the major products of this mapping experiment was the fully protected probe. The conventional interpretation of this result is that a polycistronic

pyrG eno mRNA annealed to the probe and protected against nuclease S1 digestion. An alternative possibility, not presently excluded, is that two overlapping monocistronic *pyrG* and *eno* RNA molecules can anneal to the probe forming a tripartate nuclease S1-resistant structure (37). The other major mRNA of approximately 400 nucleotides should correspond either to a *pyrG* transcript having a 3' end at approximately nucleotide 2059 or an *eno* transcript having a 5' end at approximately nucleotide 2040. Likewise, the minor mRNA species of 420, 530, and 650 nucleotides either terminate distal to *pyrG* or initiate upstream of *eno*. Further experiments are required to determine whether multiple *pyrG* and *eno* mRNA molecules arise from transcription termination after *pyrG* and transcription initiation prior to *eno* or whether a primary *pyrG eno* mRNA undergoes processing. Since *pyrG* expression appears to be constitutive (3), there are no obvious regulatory barriers to a polycistronic *pyrG eno* transcriptional unit.

Acknowledgments—We thank James Friesen for providing *pyrG* plasmid pNF1519 and *E. coli* strain JF646, Mark Hermodson for sequenator analyses, and Dan Ebbole for insightful discussions.

REFERENCES

- Buchanan, J. M. (1973) *Adv. Enzymol. Relat. Areas Mol. Biol.* **39**, 91–183
- Koshland, D. E., Jr., and Levitzki, A. (1974) *The Enzymes* **10**, 539–559
- O'Donovan, G., and Neuhard, J. (1970) *Bacteriol. Rev.* **34**, 278–343
- Kawamura, M., Keim, P. S., Goto, Y., Zalkin, H., and Heinrikson, R. L. (1983) *J. Biol. Chem.* **253**, 4659–4668
- Nichols, B. P., Miozzari, G. F., van Cleemput, M., Bennett, G. N., and Yanofsky, C. (1980) *J. Mol. Biol.* **142**, 503–517
- Kaplan, J. B., and Nichols, B. P. (1983) *J. Mol. Biol.* **168**, 451–468
- Piette, J., Nyunoya, H., Lusty, C. J., Cunin, R., Weyens, G., Crabeel, M., Charlier, D., Glansdorff, N., and Piérard, A. (1984) *Proc. Natl. Acad. Sci. U. S. A.* **81**, 4134–4138
- Zalkin, H., Argos, P., Narayana, S. V. L., Tiedeman, A. A., and Smith, J. M. (1985) *J. Biol. Chem.* **260**, 3350–3354
- Kaplan, J. B., Merkel, W. K., and Nichols, B. P. (1985) *J. Mol. Biol.* **183**, 327–340
- Werner, M., Feller, A., and Piérard, A. (1985) *Eur. J. Biochem.* **146**, 371–381
- Tso, J. Y., Zalkin, H., van Cleemput, M., Yanofsky, C., and Smith, J. M. (1982) *J. Biol. Chem.* **257**, 3525–3531
- Walker, J. E., Gay, N. J., Saraste, M., and Eberle, A. N. (1984) *Biochem. J.* **224**, 799–815
- Mäntsälä, P., and Zalkin, H. (1984) *J. Biol. Chem.* **259**, 14230–14236
- Paluh, J. L., Zalkin, H., Betsch, D., and Weith, H. L. (1985) *J. Biol. Chem.* **260**, 1889–1894
- Amuro, N., Paluh, J. L., and Zalkin, H. (1985) *J. Biol. Chem.* **260**, 14844–14849
- Friesen, J. D., An, G., and Fiel, N. P. (1978) *Cell* **15**, 1187–1197

17. Birnboim, H. C., and Doly, J. (1979) *Nucleic Acids Res.* **7**, 1513-1525
18. Vogel, H. J., and Bonner, D. M. (1956) *J. Biol. Chem.* **218**, 97-102
19. Anderson, P. M. (1983) *Biochemistry* **22**, 3285-3292
20. Long, C. W., and Pardee, A. B. (1967) *J. Biol. Chem.* **242**, 4715-4721
21. Layne, E. (1957) *Methods Enzymol.* **3**, 447-454
22. Laemmli, U. K. (1970) *Nature* **227**, 680-685
23. Mahoney, W. C., Hogg, R. W., and Hermodson, M. A. (1981) *J. Biol. Chem.* **256**, 4350-4356
24. Sanger, F., Nicklen, S., and Coulson, A. R. (1977) *Proc. Natl. Acad. Sci. U. S. A.* **74**, 5463-5467
25. Biggen, M. D., Gibson, T. J., and Hong, G. F. (1983) *Proc. Natl. Acad. Sci. U. S. A.* **80**, 3963-3965
26. Henikoff, S. (1984) *Gene (Amst.)* **28**, 351-359
27. Queen, C., and Korn, L. J. (1984) *Nucleic Acids Res.* **12**, 581-599
28. Jinks-Robertson, S., Gourse, R. L., and Nomura, M. (1983) *Cell* **33**, 865-867
29. Berk, A. J., and Sharp, P. A. (1978) *Proc. Natl. Acad. Sci. U. S. A.* **75**, 1274-1278
30. Tiedeman, A., Smith, J. M., and Zalkin, H. (1985) *J. Biol. Chem.* **260**, 8676-8679
31. Schechtman, M. G., and Yanofsky, C. (1983) *J. Mol. Appl. Genet.* **2**, 83-99
32. Zalkin, H., Paluh, J. L., van Cleemput, M., Moye, W. S., and Yanofsky, C. (1984) *J. Biol. Chem.* **259**, 3985-3992
33. Nyunoya, H., and Lusty, C. J. (1984) *J. Biol. Chem.* **259**, 9790-9798
34. Levitzki, A., Stallcup, W. B., and Koshland, D. E., Jr. (1971) *Biochemistry* **10**, 3371-3378
35. Holland, M. J., Holland, J. P., Thill, G. P., and Jackson, K. A. (1981) *J. Biol. Chem.* **256**, 1385-1395
36. Bachmann, B. J., and Low, K. B. (1980) *Microbiol. Rev.* **44**, 1-56
37. Lopata, M. A., Sollner-Webb, B., and Cleveland, D. W. (1985) *Mol. Cell. Biol.* **5**, 2842-2846

Supplementary Material to

Nucleotide Sequence of *Escherichia coli* pyrG Encoding CTP Synthetase

Manli Weng, Christopher A. Makaroff, and Howard Zalkin

EXPERIMENTAL PROCEDURES

Plasmids, Strains and Media - *E. coli* strain JF646 (relevant genotype, *pyrE pyrG cdd argE his4 proA thr1 thrII recA*) and plasmid pNF1519 (16) were provided by James Friesen, University of Toronto. Plasmids were isolated from transformants by the alkaline lysis method (17). This procedure was scaled up for the preparative isolation of plasmid DNA. CsCl/Ethidium bromide centrifugation was included as a final step. For enzyme production strain JF646/pMW5 was grown in media containing salts (18), 0.5% glucose, 0.5% acid hydrolyzed casein, 2 mg/l thiamine, 0.22% uracil. Cells were harvested in late log to early stationary phase.

Subcloning pyrG - Strain JF646 is a pyrimidine auxotroph that requires cytidine for growth. *pyrG* was subcloned from pNF1519, a pBR322 derivative, to pUC8. *pyrG* plasmids were selected in strain JF646, grown with uracil, by complementation of the chromosomal *pyrG* mutation.

Enzyme Purification - CTP synthetase was purified to electrophoretic homogeneity by the method of Anderson (19). Crude extracts of plasmid-bearing strain JF646 contained approximately 50-fold elevated levels of CTP synthetase (19), thus allowing the phenyl-Sepharose and Sephadex G-200 chromatographic steps to be omitted. CTP synthetase activity was determined at 23°C by the method of Long and Pardee (20) using the assay mixture specified by Anderson (19). The protein content of crude fractions was determined by the Biuret method (21) and for the purified enzyme by amino acid analysis. An extinction coefficient, $E_{1\%}^{1\text{cm}}$ at 280 nm of 8.33 was determined. The specific activity of the purified enzyme was 2.3 units/mg protein, assayed at 23°C. A unit of activity corresponds to the production of 1 μmol CTP/min at 23°C. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (22) was used to assess homogeneity and for estimation of subunit molecular weight.

Amino Acid Analysis and Amino Acid Sequencing - Samples for amino acid analysis were hydrolyzed in 6 N HCl for 22 h, 44 h and 66 h *in vacuo*. Analyses were performed with a Durrum D500 amino acid analyzer. A Beckman 8900 sequencer was employed for automated Edman degradation using the procedures of Mahoney *et al.* (23).

DNA Sequencing - DNA sequences were determined by the procedure of Sanger *et al.* (24). The polyacrylamide/urea gel electrophoresis described by Biggen *et al.* (25) was used for resolving the DNA fragments. DNA fragments from digests of pMW5 or the 2.6 kb Sall-PstI insert were ligated into the appropriate cloning sites in M13mp18 or M13mp19. Digests were obtained using RsaI, TaqI, HpaII and restriction enzymes having six base pair recognition sequences. A set of 13 clones containing overlapping *pyrG* fragments from the BamHI-PstI region and 3 clones from the NruI-BamHI segment were obtained by the exonuclease III procedure of Henikoff (26). M13 recombinants were transformed into JM101. DNA and protein sequences were analyzed by computer (27).

Nuclease S1 Mapping - RNA was isolated (28) from strain W3110 grown to midlog phase in minimal media. A 462 nucleotide NruI-BamHI probe, nucleotides 12-473 (Fig. 3), was used to map the 5' end of *pyrG*. The NruI-BamHI fragment was cloned into M13mp18 and M13mp19. ^{32}P -labeled probes were synthesized by primer extension using 17 base sequencing primer, $[\gamma\text{-}^{32}\text{P}]\text{dCTP}$, TTP, dATP, dGTP and DNA polymerase Klenow fragment. After primer extension the radioactive probe was cut out of M13 using flanking restriction enzyme sites in the poly-linker region. Coding strand hybridization probe, complementary to mRNA was obtained from M13mp18. A noncoding strand control having the same sequence as mRNA was obtained from M13mp19. For a second series of experiments the 462 bp NruI-BamHI fragment was isolated from pMW5 and labeled with $[\gamma\text{-}^{32}\text{P}]\text{ATP}$ and polynucleotide kinase. DNA probes were hybridized (29) with 79 μg RNA at 54°C for 12 h. Nuclease S1 treatment (1400 units per ml) was at 37°C for 40 min. RNA-protected fragments were resolved on 5% polyacrylamide 7 M urea gels with MspI-digested pBR322 for size standard.

A 780 nucleotide KpnI-PstI probe (nucleotides 1663-2442, Fig. 3) was used to map the 3' end of *pyrG* in a similar way. Primer extension of the M13mp18 recombinant gave a coding strand hybridization probe complementary to mRNA. Primer extension from the M13mp19 recombinant was used to obtain a radioactive noncoding DNA strand to serve as a control.




Fig. 1. *E. coli pyrG* plasmids. Restriction maps are drawn approximately to scale. The symbols are: filled box, *pyrG* coding DNA; open box, *E. coli* flanking DNA; solid line, pBR322; dashed line, pUC8. Abbreviations for restriction sites are: B, BamHI; E, EcoRI; H, HindIII; K, KpnI; N, NruI; P, PstI; S, Sall.




Fig. 2. Sequencing strategy for *pyrG*. The *pyrG* coding sequence is indicated as a solid box. Numbering is from a TaqI site just upstream of the unique NruI site. Arrows indicate the extent of sequence obtained from each cloned fragment. Three sets of clones were used: A, fragments obtained using RsaI, TaqI, HpaII; B, fragments obtained from restriction sites shown on the map; C, obtained by exonuclease III digestion.




Fig. 4. Estimation of CTP synthetase subunit molecular weight by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Molecular weight reference proteins (A) are bovine serum albumin (68,000), anthranilate synthase component I (57,500), ovalbumin (43,000), α -chymotrypsinogen (25,700), anthranilate synthase component II (21,800); (X), migration of CTP synthetase. The inset shows a photograph of a stained gel. The numbers at the left refer to positions of molecular mass standards in kilodaltons.

Downloaded from www.jbc.org by on November 9, 2006

The Journal of Biological Chemistry

JBC




Fig. 5. Nuclease S1 mapping of the 5' end of *pyrG* mRNA. (A) DNA probes synthesized by primer extension. The *NruI*-*Bam*HI fragment was cloned in M13mp18 and M13mp19. Primer extension using M13mp19 yields coding strand DNA complementary to mRNA; M13mp18 yields noncoding strand DNA. Hybridization reactions contained approximately 0.02 pmol DNA probe and 79 μ g RNA. Hybridization was at 54°C for 12 h. Lane 1, *Msp*I-digested pBR322 size standard; lane 2, RNA protected fragments of coding strand probe; lane 3, undigested coding strand probe; lane 4, non coding strand probe incubated with RNA and digested with nuclease S1; lane 5, undigested non coding strand probe. (B) *NruI*-*Bam*HI probe 5' end labeled. Hybridization reactions contained approximately 0.3 pmol DNA probe and 79 μ g RNA. Lane 1, size standard; lane 2, probe, RNA, 700 units per ml nuclease S1; lane 3, probe, RNA, 1400 units per ml nuclease S1; lane 4, undigested probe. Lanes 1 and 4 were exposed for 4 h at -20°C with an intensifying screen, lanes 2 and 3 for 12 h at -70°C with an intensifying screen. (C) Nuclease S1-digested fragments from (A) electrophoresed alongside a dideoxy sequencing ladder of the *NruI*-*Bam*HI fragment. The arrows mark the positions of two nuclease S1-digested fragments. The lower major band corresponds to an mRNA 5' end at approximately 303 in the nucleotide sequence. The upper minor band corresponds to an mRNA 5' end at approximately 222 in the nucleotide sequence.

Fig. 6. Nuclease S1 mapping of the 3' end of *pyrG* mRNA. DNA probes were synthesized by primer extension. The 3'-distal *Xp*NI-*Pst*II fragment was cloned into M13mp18 and M13mp19 to give coding and noncoding strand probes, respectively. Lane 1, *Msp*I-digested pBR322 size standard; lane 2, RNA-protected fragments of coding strand probe; lane 3, undigested coding strand probe; lane 4, non coding strand probe incubated with RNA and digested with nuclease S1; lane 5, undigested non coding strand probe. Arrowheads point to major protected fragments, circles mark minor protected fragments.